Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13300984 | 1.00 | CHRM1 (0.58) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9094744 | 1.00 | CHRM1 (0.58) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL10569051 | 0.89 | CHRM1 (0.47) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL12674256 | 0.85 | CHRM1 (0.43) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9097759 | 0.83 | CHRM1 (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13038562 | 0.83 | CHRM1 (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL11849760 | 0.80 | CHRM1 (0.54) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Oxalic Acid SCHEMBL10569543 | 0.80 | CHRM1 (0.51) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9289352 | 0.79 | CHRM2 (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL96686 | 0.79 | CHRM2 (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| US-20170334903-A1 | METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2017-11-23 | — | — | US | disclosed |
| US-9682975-B2 | Method of preparing glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-06-20 | — | — | US | disclosed |
| US-9012451-B2 | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists | NOVARTIS AG (CH) | 2015-04-21 | — | — | US | disclosed |
| US-20120220599-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334903-A1 | METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM1 4833/4885CHRM2 4811/4885CHRM4 4850/4885 |
| US-20120220599-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRM1 18/4885CHRM2 21/4885CHRM4 20/4885 |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, CMA1 | CHRM1 2922/4885CHRM2 2794/4885CHRM4 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.